

Immunoglobulin shortage : Practice modifications and clinical outcomes in a reference centre

N'kaoua E.¹, Mestivier E.¹, Campana-salort E.², Verschueren A.², Delmont E.², Grapperon A.M.², Attarian S.^{2,3}, Roche M.^{1,4}

1 ASSISTANCE PUBLIQUE - HÔPITAUX DE MARSEILLE, SERVICE CENTRAL DES OPÉRATIONS PHARMACEUTIQUES SCOP, MARSEILLE, FRANCE. 2 ASSISTANCE PUBLIQUE - HÔPITAUX DE MARSEILLE, CENTRE DE REFERENCE DES MALADIES NEUROMUSCULAIRES ET SLA, MARSEILLE, FRANCE. 3AIX-MARSEILLE UNIVERSITY, MEDICAL GENETICS- INSERM UMR 1251, MARSEILLE, FRANCE. 4AIX-MARSEILLE UNIVERSITY, ICR- UMR CNRS7273, MARSEILLE, FRANCE



5PSQ-147

Background and importance


An enlargement in the number of indications of intravenous immunoglobulins (IVIg) in recent years has resulted in an increase in the consumption of these products. A lack of raw material has led to IVIg shortage. (1)

Aim and objectives

The objective of this work was to evaluate the impact of this situation on patient management in one French university centre considering practice modifications and clinical outcomes..


Material and methods

All patients treated with IVIg for chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and myasthenia Gravis were included from October 2017 to October 2018. The analysis of practices was carried out between 2016 and 2019.





17 patients (15%) presented a clinical deterioration after those changes



Conclusion and relevance

Our study showed a rather important number of IVIg prescriptions changes related to IVIG shortage during considered period. These changes had a negative impact on the clinical status of some patients. The interest of this study is essential because of the fragility of the post coronavirus disease period related to a lack of plasma from which blood products derive.

1. Sewell WAC, Kerr J, Behr-Gross M-E, Peter H-H, Kreuth Ig Working Group. European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014 Aug;44(8):2207–14